口服抗凝药对系统性硬化相关毛细血管前肺动脉高压的疗效:EUSTAR队列研究
该回顾性队列研究纳入614例经右心导管确诊毛细血管前肺动脉高压的系统性硬化患者,143例(23%)在右心导管时使用口服抗凝药。使用口服抗凝药与生存(HR 0.983,95%CI 0.724-1.334)或肺动脉高压恶化(HR 1.070,95%CI 0.811-1.412)均无显著关联,倾向性评分匹配后及无间质性肺病亚组结果一致。
要点
- 口服抗凝药与毛细血管前肺动脉高压的系统性硬化患者生存无显著关联。
- 口服抗凝药与肺动脉高压恶化无显著关联。
- 倾向性评分匹配后及无间质性肺病亚组结果一致。
核心结论
- 在该系统性硬化合并毛细血管前肺动脉高压的大队列中,未观察到口服抗凝药与生存或肺动脉高压恶化相关的临床获益。
研究设计与样本
- 回顾性队列研究,纳入欧洲硬皮病试验与研究数据库(EUSTAR)中经右心导管确诊毛细血管前肺动脉高压的系统性硬化患者614例。
主要发现
- 614例患者中143例(23%)在右心导管时使用口服抗凝药。
- 口服抗凝药使用与生存无显著关联(HR 0.983,95%CI 0.724-1.334)。
- 口服抗凝药使用与肺动脉高压恶化无显著关联(HR 1.070,95%CI 0.811-1.412)。
- 倾向性评分匹配后及230例无间质性肺病的系统性硬化合并毛细血管前肺动脉高压亚组中,结果保持一致。
临床怎么用
- 对于系统性硬化合并毛细血管前肺动脉高压患者,口服抗凝药未显示生存或肺动脉高压恶化方面的获益,个体化治疗决策需权衡。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The role of anticoagulation in systemic sclerosis (SSc) with precapillary pulmonary hypertension (PH) remains controversial, with conflicting evidence regarding its impact on survival, including potential harmful effects. Aiming to address this research gap, we evaluated both mortality and PH worsening in a large SSc-precapillary PH cohort, additionally accounting for SSc-specific risk factors in our analyses, to better inform individualized treatment decisions. METHODS: This retrospective cohort study included SSc patients from the European Scleroderma Trials and Research database with precapillary PH confirmed by right heart catheterization (RHC). The association of oral anticoagulants (OAC) use with survival and PH worsening was assessed using Kaplan-Meier estimates and multivariable Cox regression models. To minimize confounding, propensity score matching was additionally performed. RESULTS: Among 614 patients included, 143 (23%) received OAC at the time of RHC. At baseline, patients on OAC had worse hemodynamic parameters. No significant association was found between OAC use and survival (HR 0.983 95%CI 0.724-1.334) or PH worsening (HR 1.070 95%CI 0.811-1.412). These findings remained consistent after propensity score matching and in the subgroup of 230 SSc patients with precapillary PH without interstitial lung disease. CONCLUSION: In this large SSc cohort with precapillary PH, we did not observe any clinical benefit associated with OAC, neither in terms of survival nor of PH worsening. Further prospective studies are needed to determine whether specific patient subgroups may benefit from anticoagulation therapy.
引用
- Farina N, Bellando Randone S, Jenssen-Bjørkekjær H, et al. Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study. Rheumatology (Oxford). 2026. PMID: 42758145. doi:10.1093/rheumatology/keag516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。